ENA Respiratory, a clinical-stage pharmaceutical company developing antiviral host defense immune enhancers to minimize the impact of respiratory viral infections in at-risk populations, announces ...
The prevalence of serious head and neck infections among children doubled from 2021 to 2023, according to findings published in The Journal of Pediatrics.“Rarely, common respiratory infections such as ...